BioSpace News Archive

Duke Street Bio, a UK-based biotech focusing on the discovery of novel precision medicine-based cancer therapies, today announced the strengthening of its executive leadership team with the appointment of Dónal Landers, MB BCh BAO, MBA, DPM, FFPM as Chief Medical Officer.

Biodexa Pharmaceuticals PLC announces that it has issued to various US investors 7,473,095 new ordinary shares of £0.02 each in the Company, pursuant to the exercise notices in respect of 848,068 A Warrants and 646,551 B Warrants received yesterday.

Henry Schein, Inc. announced its presence at the 2023 ADSO Annual Summit, including thought-leadership presentations on the future of dentistry and intrapreneurship as well as activities to support communities in need.

PharmaForce International recently published a report in December that benchmarked the leading Immunology sales and marketing organizations in the United States.

Today, in response to the White House Cancer Moonshot, the Digital Medicine Society (DiMe) and Moffitt Cancer Center announced they are co-hosting CancerX, a new public-private partnership effort to rapidly accelerate the pace of cancer innovation in the U.S., alongside the Office of the National Coordinator for Health Information Technology (ONC) and the Office of the Assistant Secretary for Health (OASH).

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim Genomic Medicines and Rare Disease Days, which are taking place from April 3 – 4, 2023.

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the company will be participating in Cantor Fitzgerald’s The Future of Oncology Virtual Symposium being held April 3-5, 2023, in a virtual format.

Captor Therapeutics S.A. discloses the identity of the drug targets as well as associated supporting data, and provides an update on the progress in the research and development of its pipeline lead programs CT-01, CT-02 and CT-05.

Biovica, active in cancer monitoring, announces that the company has signed a commercial partnership with the European distributor TOROMEDICAL group for the commercialization of the DiviTumTKa test for clinical routine use in the Netherlands and Poland.

Burning Rock Biotech Limited, a company focused on the application of next generation sequencing technology in the field of precision oncology, reported financial results for the three months and the year ended December 31, 2022.